Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944371 · ClinicalTrials.gov registry record · Phase 1
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01944371 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT01944371, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).
Interventions
- DRUG Disulfiram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01944371
The ClinicalTrials.gov registry entry for NCT01944371 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Disulfiram is the first listed.
NCT01944371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01944371 about?
NCT01944371 is a clinical study titled "Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study". The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive...
What is the current status of trial NCT01944371?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-09. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01944371?
The interventions under investigation include: Disulfiram (DRUG).
Who is sponsoring clinical trial NCT01944371?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.